Motoko Tachihara

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Toshiaki Takahashi, Takeharu Yamanaka, Takashi Seto et al. · The Lancet Oncology · 2017 · 515 citations

Radiation Medicine, Radiation Therapy, Medicine +6

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi et al. · JAMA Oncology · 2021 · 178 citations · Full text

Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer

Masahiro Katsurada, Tatsuya Nagano, Motoko Tachihara et al. · Anticancer Research · 2019 · 97 citations · Full text

Detection of the T790M mutation of <i>EGFR</i> in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

Takayuki Takahama, Kazuko Sakai, Masayuki Takeda et al. · Oncotarget · 2016 · 71 citations · Full text

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <i>EGFR</i> -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda et al. · Clinical Cancer Research · 2021 · 70 citations · Full text